Clinical trials: Anticoagulant
Percutaneous Coronary Intervention
Registry of the Combination of Antiplatelet Agents and Anticoagulant in Atrial Fibrillation Patients With a CHA2DS2VASc Score >1 Undergoing Percutaneous Coronary Interventions
Patients undergoing percutaneous coronary intervention (PCI) with stent implantation and requiring chronic anticoagulation for atrial fibrillation (AF) with a CHA2DS2-VASc >1 are required to receive triple antithrombotic therapy…
- Trial name
- NCT03012906
- Testing
- the prevalence of ischemic events
- Where
- France
- Volunteers
- 500 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Severe Preeclampsia, Antiphospholipid Syndrome
Antiphospholipid Antibodies and Early Severe Preeclampsia.
The Antiphospholipid Syndrome is an immune disease where the presence of antibodies directed against cell membrane phospholipids (antiphospholipid antibodies) can cause an hypercoagulable state that causes thrombosis and…
- Trial name
- NCT01538121
- Where
- Panama
- Volunteers
- 310 people
- Sponsor
- Saint Thomas Hospital, Panama
Non-valvular Atrial Fibrillation
Exploratory Observation of Two Short-term Regimens After LAA Occlusion by LAMax LAAC® Device for Subjects With Non-valvular Atrial Fibrillation
This is a prospective, single-center, randomized, exploratory clinical observation to explore the overall benefit of short-term dual antiplatelet or novel oral anticoagulant regimens after left atrial appendage (LAA) occlusion by…
- Trial name
- NCT05761704
- Testing
- Dual antiplatelet, Novel oral anticoagulant
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Complication
Prevention of Complications (SARS-CoV-2): Clinical Study
Viral diseases have always posed a threat to public health. Recently, the SARS-Cov2 virus spread in an epidemic that began in China and soon spread globally, making its study extremely relevant, in order to seek mechanisms to…
- Trial name
- NCT04788355
- Testing
- Control group (standard hospital treatment), Group Hydroxychloroquine, Group Hydroxychloroquine and apixaban
- Where
- Brazil
- Volunteers
- 176 people
- Sponsor
- Universidade do Vale do Sapucai
Venous Malformation, Low Flow, Anticoagulants
A Study of Direct Oral Anticoagulants in Patients with Painful Venous Malformations with Localized Intravascular Coagulation
There are two parts of the study. In Part 1, the invesitgaotrs want to investigate whether treatment with apixaban improves pain and quality of life in patients with painful venous malformations The participants are randomized to…
- Trial name
- AVA (NCT06729034)
- Testing
- Apixaban (Eliquis)
- Where
- Norway
- Volunteers
- 20 people
- Sponsor
- Oslo University Hospital
Cerebral Venous Thrombosis
Treatment Outcomes of Direct Oral Anticoagulants in Cerebral Venous Thrombosis in Vietnam
This prospective, single-arm observational cohort study aims to evaluate the real-world effectiveness and safety of direct oral anticoagulants (DOACs), specifically dabigatran or rivaroxaban, in patients with cerebral venous…
- Trial name
- DCVT-VN25 (NCT07083609)
- Testing
- Dabigatran, Rivaroxaban
- Where
- Vietnam
- Volunteers
- 69 people
- Sponsor
- Hieu Trung Dinh
Venous Thromboembolism
Shared Decision-making Process for Unprovoked vEnous THromboEmbolism Management. (ETHER )
Venous thromboembolism (VTE) including deep vein thrombosis (DVT) and pulmonary embolism (PE) is a frequent disease and the third most common cause of cardiovascular death in the world after myocardial infarction and stroke.
- Trial name
- ETHER (NCT06731244)
- Testing
- Usual Care Group, shared decision-making process
- Where
- 20 sites in France
- Volunteers
- 2,400 people
- Sponsor
- University Hospital, Brest
Congenital Heart Disease, Atrial Arrhythmia
Apixaban in Adults With Congenital Heart Disease and Atrial Arrhythmias: the PROTECT-AR Study
The purpose of this study is to evaluate the safety and efficacy of apixaban for the prevention of thromboembolism in adult patients with congenital heart disease (CHD) and non-valvular atrial arrhythmias (AA)
- Conditions
- Congenital Heart Disease, Atrial Arrhythmia, Thromboembolism, Anticoagulants Causing Adverse Effects in Therapeutic Use
- Trial name
- PROTECT_AR (NCT03854149)
- Where
- 4 sites in Greece
- Volunteers
- 218 people
- Sponsor
- AHEPA University Hospital
Antithrombotic Agents Management
Management of Anticoagulant Therapy in Non-cardiac Surgery.
The perioperative treatment of patients receiving long-term anticoagulant therapy is challenging. This is attributed to the continuation of anticoagulants perioperatively, which is associated with an increased bleeding risk while…
- Trial name
- NCT04766606
- Where
- Greece
- Volunteers
- 614 people, healthy volunteers welcome
- Sponsor
- University of Ioannina
Pulmonary Embolism, Venous Thromboembolism
Implementing Prescriber-Pharmacist Collaborative Care for Evidence-based Anticoagulant Use
The researchers hypothesize that existing-prescription notifications directed to pharmacists are more likely to lead to a prescription change than existing-prescription notifications directed to prescribers.
- Conditions
- Pulmonary Embolism, Venous Thromboembolism, Atrial Fibrillation
- Trial name
- NCT05351749
- Testing
- New-prescription Alert, New-prescription Alert with referral option, Existing-prescription notification to prescriber
- Where
- United States
- Volunteers
- 306 people
- Sponsor
- University of Michigan
Atrial Fibrillation, Anticoagulants
Clinical Decision Support Tool for Improving the Adequacy of Anticoagulant Therapy in Non-valvular Atrial Fibrillation
Atrial fibrillation (AF) is the most common cardiac arrhythmia and increases the risk of ischemic stroke 4-5-fold. The prevention of complications is based on oral or antiplatelet anticoagulant treatment.
- Conditions
- Atrial Fibrillation, Anticoagulants, Clinical Decision Support Systems
- Trial name
- NACOs (NCT03367325)
- Testing
- CDS-NVAF
- Where
- Spain
- Volunteers
- 63,001 people
- Sponsor
- Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
Venous Thrombosis, Pulmonary Embolism
Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)
This prospective cohort study will provide information about: characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed Warfarin for the first time…
- Conditions
- Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation, Acute Coronary Syndrome
- Trial name
- NCT01947998
- Testing
- Rivaroxaban (Xarelto, Bay59-7939), Warfarin, Antiplatelet drugs
- Where
- United Kingdom
- Volunteers
- 50,299 people
- Sponsor
- Bayer
Head Injury, Traumatic Brain Injury
Selective CT for Anticoagulated Head Injured Patients
The goal is to derive and a clinical decision rule for safe exclusion of traumatic brain injury without neuroimaging in head-injured ED patients who take anticoagulant medications. The objectives are to: 1.
- Conditions
- Head Injury, Traumatic Brain Injury, Intracranial Hemorrhage, Traumatic, Blunt Head Injury
- Trial name
- Can-SCAHn (NCT05364749)
- Where
- 7 sites in Canada
- Volunteers
- 4,000 people
- Sponsor
- Dr. Kerstin de Wit
Older Adults (65 Years and Older), Falls
Healthcare Services for Older People Who Have Fallen With Potential Head Injury
Every year, one in three older people (>65 years old) experience a fall. Older people may have long-term health conditions and take medications that can increase their risk of bleeding (blood thinners).
- Conditions
- Older Adults (65 Years and Older), Falls, Head Injury
- Trial name
- Anti-HI-Falls (NCT07111871)
- Where
- United Kingdom
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Portsmouth Hospitals NHS Trust
Venous Thromboembolic Disease
Best Antithrombotic Therapy in Patients With Acute Venous ThromboEmbolism While Taking Antiplatelets
Venous thromboembolism (VTE) and atherosclerotic cardiovascular disease share common risk factors and frequently coexist in the same patients.
- Trial name
- BAT-VTE (NCT05627375)
- Testing
- Full-dose anticoagulant therapy (AC), Antiplatelet therapy (AP)
- Where
- 28 sites in France
- Volunteers
- 1,400 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Ischem Heart Disease, Primary Coronay Intervention
CHAOS Registry Study
INTRODUCTION: About 6-8% of patients undergoing PCI have an indication for long-term oral anticoagulants (OACs) due to various conditions such as atrial fibrillation (AF), mechanical heart valves, or venous thromboembolism.
- Conditions
- Ischem Heart Disease, Primary Coronay Intervention, Oral Anticoagulants, Atrial Fibrillation
- Trial name
- CHAOS (NCT03558295)
- Testing
- Oral Anticoagulant
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- A.O.U. Città della Salute e della Scienza
Chronic Hemolysis, VKA
Possibility to Stop Perdialytic Heparin Therapy in Hemodialysed Patients With HeprAN ™ Membrane and Treated by Long-term Anticoagulation With VKA
Use HeprAN ™ membrane (coated with heparin) should be allow the success of dialysis sessions, with adequate dialysis parameters, in patients treated by long-term anticoagulation with VKA, without addition of heparin perdialytic.
- Conditions
- Chronic Hemolysis, VKA, Anticoagulants / Administration & Dosage, Coated Materials
- Trial name
- REMARK (NCT04462614)
- Testing
- Decrease per-dialytic heparin therapy
- Where
- France
- Volunteers
- 49 people
- Sponsor
- CHU de Reims
Infection, Heart Failure
Home Hospital for Suddenly Ill Adults
The investigators propose a home hospital model of care that substitutes for treatment in an acute care hospital. Limited studies of the home hospital model have demonstrated that a sizeable proportion of acute care can be…
- Conditions
- Infection, Heart Failure, COPD, Asthma
- Trial name
- NCT03524222
- Testing
- Home Hospitalization
- Where
- 2 sites in United States
- Volunteers
- 3,000 people
- Sponsor
- Brigham and Women's Hospital
Anticoagulation With Direct Oral Anticoagulants
Point-of-Care Testing of Coagulation in Patients Treated With Direct Oral Anticoagulants 1
The investigators study aims to test the correlation between the CoaguChek point-of-care testing (POCT) device (Roche, Switzerland) and low plasma levels of all three currently approved direct oral anticoagulants (DOAC…
- Trial name
- POCT-DOAC 1 (NCT02371044)
- Volunteers
- 60 people
- Sponsor
- University Hospital Tuebingen
Stable Target INR
Improving Anticoagulant Therapy Through Warfarin Metabolite Profiling
Clinically relevant biomarkers for warfarin identified in this study will provide crucial leads for subsequent studies to assess their predictive value during anticoagulant therapy.
- Trial name
- NCT01964794
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- University of Arkansas